Systemic lupus erythematosus complicated by disseminated intravascular coagulation: The role of serum soluble cell surface markers

Clinical and Experimental Rheumatology

Volumn 15, Issue 6, 1997, Pages 671-675

  Kogure, T ^a   Fujinaga, H ^a   Nozaki, K ^a   Sakai, S ^a   Itoh, T ^a   Terasawa, K ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Disseminated intravascular coagulation; Soluble CD23; Soluble CD4; Soluble CD8; Systemic lupus erythematosus; Thrombomodulin

Indexed keywords

CD23 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DNA ANTIBODY; LYMPHOCYTE SURFACE MARKER;

ADULT; APHTHOUS STOMATITIS; ARTICLE; CASE REPORT; CELL SURFACE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHEMA; FEMALE; FEVER; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGENS, CD4; ANTIGENS, CD8; BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, IGE; THROMBOMODULIN;

EID: 0030777914     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. KERR LD, SPIERA H, ALEDORT LN: Acute disseminated intravascular coagulation as a complication of systemic lupus erythematosus. NY State J Med 1987; 87: 181-3.
2. SHIMAMOTO Y, OHTA A, SANO M, SUGA K, YAMAGUCHI M: Improved or fatal disseminated intravascular coagulation in systemic lupus erythematosus. Am J Hematol 1993; 42: 191-5.
3. LINKER-ISRAELI M, HYUN S, WALLACE DJ, KLINBERG JR: Soluble CD8 molecules in systemic lupus erythematosus (SLE). Rev Esp Rheumatol 1993; 20 (Suppl. 1): 420 (Abstract).
4. MORIMOTO S, TOKANO Y, TAKASAKI Y, HASHIMOTO H: Relation between the levels of soluble CD4, CD8 and CD23 molecules in sera and clinical manifestations and laboratory data in patients with systemic lupus erythematosus. Jpn J Rheumatol 1996; 301-7.
5. AL-JANADI M, AL-WABEL A, RAZIUDDIN S: Soluble CD23 and interleukin-4 levels in autoimmune chronic active hepatitis and systemic lupus erythematosus. Clin Immunol Immunopathol 1994; 71: 33-7.
6. LINKER-ISRAELI M, HYUN S, O-CHEN T, WALLACE DJ, BANKS K, KLINBERG JR: Elevated in vivo and in vitro secretion of CD8-α molecules in patients with systemic lupus erythematosus. J Immunol 1994;152:3158-67.
7. TAN EM, AS COHEN, JF FRIES et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7
8. TER BORG EJ, HORST G, HUMMEL EJ, LIMBURG PC, KALLENBERG CG: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 1990; 33: 634-43.
9. WHITAKER AN, EMMERSON BT: Acute disseminated intravascular coagulation in systemic lupus erythematosus. Aust NZ J Med 1972; 2: 182-7.
10. SIEGAL T, SELIGSOHN U, AGHAI E, MODAN M: Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): A study of cases. Thromb Haemost 1978; 39: 122-34.
11. BIRD AG, LENDRUM R, ASHERSON RA, HUGHES GR: Disseminated intravascular coagulation, antiphospholipid antibodies, and ischemic necrosis of extremities. Ann Rheum Dis 1987; 46: 251-5.
12. TANAKA M, KOBAYASHI S, TAMURA N, HASHIMOTO H, HIROSE S: Disseminated intravascular coagulation in a patient with systemic lupus erythematosus with lupus anticoagulant. Intern Med 1993; 32: 513-7.
13. MERRIL JT, LAHITA RG: The antiphospholipid syndrome and SLE: Is there a clue in the link between complenent and coagulation? Lupus 1996; 5: 6-10.
14. LIE JT: Vasculopathy in the antiphospholipid syndrome: Thrombosis or vasculitis, or both? J Rheumatol 1989; 16: 713-5.
15. LIE JT: Vasculitis in the antiphospholipid syndrome: Culprit or consort? J Rheumatol 1994; 21: 397-9.
16. KAPLAN AP, SILVERBERG M, DUNN JT, MILLER G: Mechanisms for Hageman factor activation and role of HMW kininogen as a coagulation cofactor. Ann NY Acad Sci 1981; 370: 253-60.
17. DITTMAN WA, MAJERUS PW: Structure and function of thrombomodulin. A natural anticoagulant. Blood 1990; 75: 329-36.
18. TOKANO Y, HISHIKAWA T, HIROSE T et al.: HLA-DP-positive T cells in patients with systemic lupus erythematosus. Autoimmunity 1990; 5: 179-83.
19. SWAAK AJG, HINTZEN RQ, HUYSEN V, VAN DEN BRINK HG, SMEENK JT: Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course. Clin Rheum 1995; 14: 293-300.
20. UMLAND SP, GO NF, CUPP JE, HOWARD M: Responses of B cells from autoimmune mice to IL-5. J Immunol 1989; 142: 1528-35.
21. BANSAL A, ROBERTS T, HAY EM, KAY R, PUMPHREY RSH, WILSON PB: Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 1992; 89: 452-5.
22. SAWADA S, HASHIMOTO H, IIJIMA S et al.: Immunologic significance of increased soluble CD8/CD4 molecules in patients with active systemic lupus erythematosus. J Clin Lab Ana 1993; 7: 141-6
23. SPRONK PE, TER BORG EJ, HUITEMA MG, LIMBURG PC, KALLENBERG CGM: Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: A prospective study. Ann Rheum Dis 1994; 53: 235-239.
24. SAMSONOV MY, TILTZ GP, EGOROVA O et al.: Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 29-32.